1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective
of the Study
2.2. Baseline
Methodology
2.3. Key
Industry Partners
2.4. Major
Association and Secondary Sources
2.5. Forecasting
Methodology
2.6. Data
Triangulation & Validation
2.7. Assumptions
and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5.
Global Nucleic Acid
Therapeutics CDMO Market Outlook
5.1. Market Size & Forecast
5.1.1.
By Value
5.2. Market Share & Forecast
5.2.1.
By Type
(Gene Therapy, RNA-based Therapies)
5.2.2.
By Service (Process Development &
Optimization, Manufacturing Services, Analytical and Quality Control Services,
others)
5.2.3.
By Application (Oncology, Genetic
Disorders, Infectious Diseases, others)
5.2.4.
By Region
5.2.5.
By Company (2023)
5.3. Market Map
6.
Asia Pacific Nucleic
Acid Therapeutics CDMO Market Outlook
6.1. Market Size & Forecast
6.1.1.
By Value
6.2. Market Share & Forecast
6.2.1.
By Type
6.2.2.
By Service
6.2.3.
By Application
6.2.4.
By Country
6.3. Asia Pacific: Country Analysis
6.3.1.
China Nucleic Acid
Therapeutics CDMO Market Outlook
6.3.1.1.
Market Size & Forecast
6.3.1.1.1.
By Value
6.3.1.2.
Market Share & Forecast
6.3.1.2.1.
By Type
6.3.1.2.2.
By Service
6.3.1.2.3.
By Application
6.3.2.
India Nucleic Acid
Therapeutics CDMO Market Outlook
6.3.2.1.
Market Size & Forecast
6.3.2.1.1.
By Value
6.3.2.2.
Market Share & Forecast
6.3.2.2.1.
By Type
6.3.2.2.2.
By Service
6.3.2.2.3.
By Application
6.3.3.
Australia Nucleic
Acid Therapeutics CDMO Market Outlook
6.3.3.1.
Market Size & Forecast
6.3.3.1.1.
By Value
6.3.3.2.
Market Share & Forecast
6.3.3.2.1.
By Type
6.3.3.2.2.
By Service
6.3.3.2.3.
By Application
6.3.4.
Japan Nucleic Acid
Therapeutics CDMO Market Outlook
6.3.4.1.
Market Size & Forecast
6.3.4.1.1.
By Value
6.3.4.2.
Market Share & Forecast
6.3.4.2.1.
By Type
6.3.4.2.2.
By Service
6.3.4.2.3.
By Application
6.3.5.
South Korea Nucleic
Acid Therapeutics CDMO Market Outlook
6.3.5.1.
Market Size & Forecast
6.3.5.1.1.
By Value
6.3.5.2.
Market Share & Forecast
6.3.5.2.1.
By Type
6.3.5.2.2.
By Service
6.3.5.2.3.
By Application
7.
Europe Nucleic Acid
Therapeutics CDMO Market Outlook
7.1. Market Size & Forecast
7.1.1.
By Value
7.2. Market Share & Forecast
7.2.1.
By Type
7.2.2.
By Service
7.2.3.
By Application
7.2.4.
By Country
7.3. Europe: Country Analysis
7.3.1.
France Nucleic Acid
Therapeutics CDMO Market Outlook
7.3.1.1.
Market Size & Forecast
7.3.1.1.1.
By Value
7.3.1.2.
Market Share & Forecast
7.3.1.2.1.
By Type
7.3.1.2.2.
By Service
7.3.1.2.3.
By Application
7.3.2.
Germany Nucleic Acid
Therapeutics CDMO Market Outlook
7.3.2.1.
Market Size & Forecast
7.3.2.1.1.
By Value
7.3.2.2.
Market Share & Forecast
7.3.2.2.1.
By Type
7.3.2.2.2.
By Service
7.3.2.2.3.
By Application
7.3.3.
Spain Nucleic Acid Therapeutics
CDMO Market Outlook
7.3.3.1.
Market Size & Forecast
7.3.3.1.1.
By Value
7.3.3.2.
Market Share & Forecast
7.3.3.2.1.
By Type
7.3.3.2.2.
By Service
7.3.3.2.3.
By Application
7.3.4.
Italy Nucleic Acid
Therapeutics CDMO Market Outlook
7.3.4.1.
Market Size & Forecast
7.3.4.1.1.
By Value
7.3.4.2.
Market Share & Forecast
7.3.4.2.1.
By Type
7.3.4.2.2.
By Service
7.3.4.2.3.
By Application
7.3.5.
United Kingdom Nucleic
Acid Therapeutics CDMO Market Outlook
7.3.5.1.
Market Size & Forecast
7.3.5.1.1.
By Value
7.3.5.2.
Market Share & Forecast
7.3.5.2.1.
By Type
7.3.5.2.2.
By Service
7.3.5.2.3.
By Application
8.
North America Nucleic
Acid Therapeutics CDMO Market Outlook
8.1. Market Size & Forecast
8.1.1.
By Value
8.2. Market Share & Forecast
8.2.1.
By Type
8.2.2.
By Service
8.2.3.
By Application
8.2.4.
By Country
8.3. North America: Country Analysis
8.3.1.
United States Nucleic
Acid Therapeutics CDMO Market Outlook
8.3.1.1.
Market Size & Forecast
8.3.1.1.1.
By Value
8.3.1.2.
Market Share & Forecast
8.3.1.2.1.
By Type
8.3.1.2.2.
By Service
8.3.1.2.3.
By Application
8.3.2.
Mexico Nucleic Acid
Therapeutics CDMO Market Outlook
8.3.2.1.
Market Size & Forecast
8.3.2.1.1.
By Value
8.3.2.2.
Market Share & Forecast
8.3.2.2.1.
By Type
8.3.2.2.2.
By Service
8.3.2.2.3.
By Application
8.3.3.
Canada Nucleic Acid
Therapeutics CDMO Market Outlook
8.3.3.1.
Market Size & Forecast
8.3.3.1.1.
By Value
8.3.3.2.
Market Share & Forecast
8.3.3.2.1.
By Type
8.3.3.2.2.
By Service
8.3.3.2.3.
By Application
9.
South America Nucleic
Acid Therapeutics CDMO Market Outlook
9.1. Market Size & Forecast
9.1.1.
By Value
9.2. Market Share & Forecast
9.2.1.
By Type
9.2.2.
By Service
9.2.3.
By Application
9.2.4.
By Country
9.3. South America: Country Analysis
9.3.1.
Brazil Nucleic Acid
Therapeutics CDMO Market Outlook
9.3.1.1.
Market Size & Forecast
9.3.1.1.1.
By Value
9.3.1.2.
Market Share & Forecast
9.3.1.2.1.
By Type
9.3.1.2.2.
By Service
9.3.1.2.3.
By Application
9.3.2.
Argentina Nucleic
Acid Therapeutics CDMO Market Outlook
9.3.2.1.
Market Size & Forecast
9.3.2.1.1.
By Value
9.3.2.2.
Market Share & Forecast
9.3.2.2.1.
By Type
9.3.2.2.2.
By Service
9.3.2.2.3.
By Application
9.3.3.
Colombia Nucleic
Acid Therapeutics CDMO Market Outlook
9.3.3.1.
Market Size & Forecast
9.3.3.1.1.
By Value
9.3.3.2.
Market Share & Forecast
9.3.3.2.1.
By Type
9.3.3.2.2.
By Service
9.3.3.2.3.
By Application
10.
Middle East and Africa
Nucleic Acid Therapeutics CDMO Market Outlook
10.1.
Market Size &
Forecast
10.1.1. By Value
10.2.
Market Share &
Forecast
10.2.1.
By Type
10.2.2.
By Service
10.2.3.
By Application
10.2.4. By Country
10.3.
MEA: Country
Analysis
10.3.1. South Africa Nucleic Acid Therapeutics CDMO Market
Outlook
10.3.1.1. Market Size &
Forecast
10.3.1.1.1.
By Value
10.3.1.2. Market Share &
Forecast
10.3.1.2.1.
By Type
10.3.1.2.2.
By Service
10.3.1.2.3.
By Application
10.3.2. Saudi Arabia Nucleic Acid Therapeutics CDMO Market
Outlook
10.3.2.1. Market Size &
Forecast
10.3.2.1.1.
By Value
10.3.2.2. Market Share &
Forecast
10.3.2.2.1.
By Type
10.3.2.2.2.
By Service
10.3.2.2.3.
By Application
10.3.3. UAE Nucleic Acid Therapeutics CDMO Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1.
By Value
10.3.3.2. Market Share &
Forecast
10.3.3.2.1.
By Type
10.3.3.2.2.
By Service
10.3.3.2.3.
By Application
11. Market Dynamics
11.1.
Drivers
11.2.
Challenges
12. Market Trends & Developments
12.1.
Recent Developments
12.2.
Product Launches
12.3.
Mergers &
Acquisitions
13.
Porter’s Five Forces
Analysis
13.1.
Competition in the
Industry
13.2.
Potential of New
Entrants
13.3.
Power of Suppliers
13.4.
Power of Customers
13.5.
Threat of Substitute
Product
14. Competitive Landscape
14.1. Catalent Inc.
14.1.1. Business Overview
14.1.2. Company Snapshot
14.1.3. Products & Services
14.1.4. Financials (In case of listed companies)
14.1.5. Recent Developments
14.1.6. Key Personnel Details
14.1.7. SWOT Analysis
14.2. Thermo Fisher Scientific Inc.
14.3. Lonza Group Ltd.
14.4. FUJIFILM Diosynth Biotechnologies U.S.A. Inc.
14.5. Charles River Laboratories International, Inc.
14.6.
Eurofins Genomics
14.7.
Sirion Biotech GmbH
14.8.
Oxford Biomedica Plc.
14.9.
Danaher Corp.
15. Strategic
Recommendations
16. About Us & Disclaimer